Androgen receptor gene mutations do not occur in ovarian cancer

• Published in: Anticancer research Vol. 20; no. 2A; p. 815
• Main Authors: Engehausen, D G, Tong, X W, Oehler, M K, Freund, C T, Schrott, K M, Kieback, D G
• Format: Journal Article
• Language: English
• Published: Greece 01-03-2000
• Subjects: Cystadenocarcinoma, Serous - genetics; Cystadenocarcinoma, Serous - pathology; DNA Primers; Exons; Female; Gene Expression Regulation, Neoplastic; Humans; Ovarian Neoplasms - genetics; Ovarian Neoplasms - pathology; Polymorphism, Single-Stranded Conformational; Receptors, Androgen - genetics; Risk Assessment; Tumor Cells, Cultured
• ISSN: 0250-7005

Genetic alterations have been frequently found in ovarian cancer. There is some indirect evidence indicating that mutation of the steroid receptor genes may play a role in the carcinogenesis of ovarian cancer. Human androgen receptor (hAR) gene mutations have been found in up to 50% of hormone-relapsed prostate cancer. The role of hAR mutation and its association with decreased expression in ovarian cancer has never been elucidated. In this study mutations of hAR gene in 38 human ovarian cancer cell lines with different AR expression pattern were studied using SSCP. No mutation of the hAR gene was found. Mutation of hAR gene is an infrequent event and therefore unlikely to be involved in the development of ovarian cancer. The decreased expression of hAR in advanced ovarian tumor is not due to genetic aberration of hAR. Mutation screening of hAR may not provide any information for risk assessment of developing ovarian cancer.